AbbVie Halts Another Trial With I-Mab Antibody, Slashes Deal Size

 
• By Dexter Jie Yan
  
CD47 discontinuation
AbbVie has now terminated two early global trials with I-Mab's lemzoparlimab • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D